Two years after buying CinCor Pharma for $1.3 billion, AstraZeneca has reported that the main asset in the deal, for uncontrolled or treatment-resistant hypertension, has cleared a phase 3 trial.

Reporters and editors at the Homer News and Peninsula Clarion announced their resignations on Monday, citing a decision by the papers’ corporate owners to bow to political pressure to amend an article ...